Latest news with #StridesPharmaScience
Business Standard
29-07-2025
- Business
- Business Standard
Strides Pharma Science consolidated net profit declines 97.03% in the June 2025 quarter
Sales rise 6.20% to Rs 1119.74 crore Net profit of Strides Pharma Science declined 97.03% to Rs 99.61 crore in the quarter ended June 2025 as against Rs 3351.47 crore during the previous quarter ended June 2024. Sales rose 6.20% to Rs 1119.74 crore in the quarter ended June 2025 as against Rs 1054.34 crore during the previous quarter ended June 2024. Particulars Quarter Ended Jun. 2025 Jun. 2024 % Var. Sales 1119.741054.34 6 OPM % 19.4817.87 - PBDT 179.30128.64 39 PBT 130.4182.12 59 NP 99.613351.47 -97
News18
29-07-2025
- Business
- News18
Strides Pharma PAT rises 81 pc to Rs 114 cr in Jun qtr
Agency: New Delhi, Jul 29 (PTI) Strides Pharma Science on Tuesday said its profit after tax increased 81 per cent year-on-year to Rs 114 crore for the first quarter ended June 30, 2025. The company reported a profit after tax (PAT) of Rs 63 crore for the April-June period of last year. Revenue rose to Rs 1,120 crore for the June quarter against Rs 1,054 crore in the year-ago period, Strides Pharma Science said in a regulatory filing. 'Our focus on cost management and diligent execution has enabled us to deliver robust results," Strides Pharma Science MD & Group CEO Badree Komandur said. The company will enhance its R&D efforts during the year to drive sustainable long-term growth, he added. Shares of Strides Pharma were trading 4.71 per cent higher at Rs 965.95 apiece on the BSE. PTI MSS MSS SHW Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Mint
30-05-2025
- Business
- Mint
Stock to buy for short-term: This multibagger small-cap stock is Axis Securities' momentum pick. Do you own?
Stock to buy for short-term: Strides Pharma Science share price was volatile on Friday amid weakness in the broader Indian stock market. Strides Pharma Science shares opened higher and gained as much as 1.49% to reach an intraday high of ₹ 793.50 apiece on the BSE. The smallcap stock, however, succumbed to selling pressure and was trading lower, hitting an intraday low of ₹ 773.00 apiece, falling 1.12%. Brokerage firm Axis Securities has picked Strides Pharma Science shares as its momentum stock pick as it believes the small-cap has the potential to see an upside of over 18% in the short-term. Axis Securities recommends a 'Buy' call on Strides Pharma Science shares, with a target price of ₹ 887-925, representing an upside potential of 18% from previous closing price. The buying range for Strides Pharma Science stock is ₹ 760-745. It maintains 'Buy' with a trend reversal level at ₹ 685. 'Strides Pharma Science share price has delivered a decisive breakout above the falling channel at ₹ 750 on the weekly chart, marked by a strong bullish candle and a surge in volumes, underscoring robust market participation and confirming the start of a medium-term uptrend,' Axis Securities said in a note. Additionally, Strides Pharma Science stock price has crossed above the weekly upper Bollinger Band, generating a technical buy signal and adding further conviction to the breakout, it added. The weekly RSI is trending higher, holding above its 50 mark and reference line, signalling strengthening momentum. A breakout above the RSI's downward-sloping trendline further reinforces the bullish setup, according to the brokerage firm. With this setup, it believes Strides Pharma Science shares appear well-poised to extend its upward move, with near-term upside targets at ₹ 887 and 925. The timeframe for the trade is 3-4 weeks. Strides Pharma Science share price has rallied 19% in one month and 25% in three months. The small-cap stock is up 10% YTD and jumped 94% in the past one year. Strides Pharma Science shares have delivered multibagger returns of 354% in two years and 310% in five years. At 10:45 AM, Strides Pharma Science share price was trading 0.36% lower at ₹ 779.00 apiece on the BSE. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Business Standard
22-05-2025
- Business
- Business Standard
Strides Pharma Science consolidated net profit rises 352.09% in the March 2025 quarter
Sales rise 14.08% to Rs 1190.39 crore Net profit of Strides Pharma Science rose 352.09% to Rs 82.19 crore in the quarter ended March 2025 as against Rs 18.18 crore during the previous quarter ended March 2024. Sales rose 14.08% to Rs 1190.39 crore in the quarter ended March 2025 as against Rs 1043.50 crore during the previous quarter ended March 2024. For the full year,net profit reported to Rs 3593.46 crore in the year ended March 2025 as against net loss of Rs 70.62 crore during the previous year ended March 2024. Sales rose 17.36% to Rs 4565.34 crore in the year ended March 2025 as against Rs 3890.13 crore during the previous year ended March 2024. Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 1190.391043.50 14 4565.343890.13 17 OPM % 18.3016.23 - 17.5813.58 - PBDT 182.6684.69 116 614.52287.89 113 PBT 133.8036.76 264 422.2674.25 469 NP 82.1918.18 352 3593.46-70.62 LP
Business Standard
30-04-2025
- Business
- Business Standard
Strides Pharma's US arm acquires four drugs to bolster portfolio
Strides Pharma Science said that its step-down wholly owned subsidiary in the US, Stride Pharma Inc, has acquired four approved ANDAs for the US Market from Nostrum Laboratories, Inc., USA. The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs (Urinary Tract Infections), Pain Management, Allergy Symptoms and Attention Deficit Disorder (ADD/ ADHD) and Narcolepsy. Two (out of the four) ANDAs acquired are commercial products and is expected to be launched within 12 months. With access to these products, Strides will expand its portfolio of niche and difficult to manufacture products. The cumulative market size for the acquired portfolio is around $57 million as per IQVIA data of 2025. Total consideration for acquisition of the said ANDAs is $ 2.075 million (Rs 17.6 crore). Strides Pharma Science is global pharmaceutical company headquartered in Bangalore, India. It develops and manufactures wide range of niche and technically complex pharmaceutical products The companys consolidated net profit jumped 77.1% to Rs 87.95 crore on 14.7% increase in net sales to Rs 1153.67 crore in Q3 FY25 over Q3 FY24. The counter declined 1.61% to end at Rs 652.55 on Tuesday, 29 April 2025.
